HCAT vs SANG: stock comparison and AI forecast
Health Catalyst, Inc. (HCAT) and Sangoma Technologies Corp (SANG) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
HCAT Health Catalyst, Inc.
- Price
- $1.46 -8.2% · 6M
- Market Cap
- $110M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
SANG Sangoma Technologies Corp
- Market Cap
- $149M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- SANG is 1.4 times larger than HCAT by market capitalization ($149M against $110M).
- SANG turns -16.0% of its revenue into net income, against -74.2% for HCAT.
- HCAT carries 0.63 times debt per unit of equity, against 0.36 times for SANG.
- Both companies share the SEC industry classification Services-Computer Programming, Data Processing, Etc..
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | HCAT | SANG |
|---|---|---|
| Market Cap | $110M | $149M |
| P/B Ratio | 0.75x | – |
| EPS | $-3.78 | $-4.81 |
| Book Value/Share | $1.93 | – |
| Revenue/Share | $3.62 | $28.82 |
| FCF/Share | $0.34 | $3.63 |
Profitability & Margins
| Metric | HCAT | SANG |
|---|---|---|
| ROE | -138.8% | -60.4% |
| ROA | -85.1% | -44.3% |
| ROIC | -112.3% | – |
| Gross Margin | 49.1% | 69.1% |
| Operating Margin | -65.7% | – |
| Net Margin | -74.2% | -16.0% |
| EBT Margin | -79.2% | -15.8% |
| Tax Rate | -0.3% | -0.8% |
Financial Health
| Metric | HCAT | SANG |
|---|---|---|
| Current Ratio | 1.70x | 0.86x |
| Quick Ratio | – | 0.70x |
| D/E Ratio | 0.63x | 0.36x |
| Financial Leverage | 1.63x | 1.36x |
| Interest Coverage | -3.9x | – |
| Working Capital | $55M | -$7M |
Cash Flow
| Metric | HCAT | SANG |
|---|---|---|
| Operating Cash Flow | $27M | $134M |
| Free Cash Flow | $26M | $121M |
| Capital Spending | -$1M | -$12M |
| FCF/Sales | 9.4% | 12.6% |
| CapEx/Sales | 0.4% | 1.3% |
Operational Efficiency
| Metric | HCAT | SANG |
|---|---|---|
| Asset Turnover | 1.15x | 2.77x |
| Receivables Turnover | 6.6x | 63.5x |
| Inventory Turnover | – | 36.0x |
| Fixed Assets Turnover | 7.9x | 149.4x |
| Days Sales Outstanding | 55 days | 6 days |
| Days Inventory | – | 10 days |
| Payables Period | 17 days | 19 days |
| Cash Conversion Cycle | – | -3 days |
Income Statement
| Metric | HCAT | SANG |
|---|---|---|
| Total Revenue | $272M | $961M |
| Operating Income | -$179M | – |
| Net Income | -$202M | -$153M |
| R&D Expense | $40M | $153M |
| SG&A Expense | $105M | – |
| Cost of Goods Sold | $138M | $297M |
Dividend & Shareholder Information
| Metric | HCAT | SANG |
|---|---|---|
| Shares Outstanding | 75M | 33M |
HCAT vs SANG: stock comparison and AI forecast
Which is bigger, HCAT or SANG?
SANG is 1.4 times larger than HCAT by market capitalization ($149M against $110M).
Which one does Intratio's AI model rank higher, HCAT or SANG?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.